Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis

To compare serum levels of the astrocyte biomarker glial fibrillary acidic protein (GFAP) in patients with amyotrophic lateral sclerosis (ALS) and neurologically healthy controls and to analyze the relations between serum GFAP (sGFAP) and phenotype in ALS.

[1]  L. Pozzi,et al.  Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis , 2022, European journal of neurology.

[2]  Stephen A. Goutman,et al.  Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis , 2022, The Lancet Neurology.

[3]  John K. Yue,et al.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders , 2022, Nature Reviews Neurology.

[4]  R. Ferrucci,et al.  Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis , 2022, European journal of neurology.

[5]  K. Blennow,et al.  Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum , 2021, JAMA neurology.

[6]  R. Ferrucci,et al.  Association of Clinically Evident Eye Movement Abnormalities With Motor and Cognitive Features in Patients With Motor Neuron Disorders , 2021, Neurology.

[7]  K. Blennow,et al.  Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease , 2021, Brain : a journal of neurology.

[8]  F. Verde,et al.  Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia , 2021, Frontiers in Neuroscience.

[9]  B. Dräger,et al.  Respiratory parameters on diagnostic sleep studies predict survival in patients with amyotrophic lateral sclerosis , 2021, Journal of Neurology.

[10]  Frontotemporal dementia with motor neuron disease , 2020, Definitions.

[11]  N. Dahodwala,et al.  Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis , 2019, Muscle & nerve.

[12]  F. Verde,et al.  Neurochemical biomarkers in amyotrophic lateral sclerosis. , 2019, Current opinion in neurology.

[13]  G. Tedeschi,et al.  Assessing anxiety and its correlates in amyotrophic lateral sclerosis: The state‐trait anxiety inventory , 2019, Muscle & nerve.

[14]  K. Fliessbach,et al.  Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[15]  T. Hortobágyi,et al.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[16]  J. Hodges,et al.  The frontotemporal dementia-motor neuron disease continuum , 2016, The Lancet.

[17]  F. Madotto,et al.  The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[18]  P. O’Rourke,et al.  Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[19]  D. Offen,et al.  Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2016, Journal of Clinical Neuroscience.

[20]  Marcella Laiacona,et al.  Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores , 2015, Neurological Sciences.

[21]  A. Chiò,et al.  Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  Xiong-hao Liu,et al.  Expression of ALS‐linked TDP‐43 mutant in astrocytes causes non‐cell‐autonomous motor neuron death in rats , 2013, The EMBO journal.

[23]  A. Al-Chalabi,et al.  A proposed staging system for amyotrophic lateral sclerosis , 2012, Brain : a journal of neurology.

[24]  J. Glass,et al.  Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[25]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[26]  J. Mendell,et al.  Astrocytes from Familial and Sporadic ALS Patients are Toxic to Motor Neurons , 2011, Nature Biotechnology.

[27]  A. Chiò,et al.  Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  J. Middeldorp,et al.  GFAP in health and disease , 2011, Progress in Neurobiology.

[29]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[30]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[31]  A. Volterra,et al.  Focal degeneration of astrocytes in amyotrophic lateral sclerosis , 2008, Cell Death and Differentiation.

[32]  A. Kertesz,et al.  The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease , 2007, Neurological Sciences.

[33]  K. Pahan,et al.  Induction of Glial Fibrillary Acidic Protein Expression in Astrocytes by Nitric Oxide , 2006, The Journal of Neuroscience.

[34]  T. Hanafusa,et al.  Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS , 2006, Neurology.

[35]  D. Royall,et al.  The FAB: A frontal assessment battery at bedside , 2001, Neurology.

[36]  I Litvan,et al.  The FAB: A frontal assessment battery at bedside , 2000, Neurology.

[37]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[38]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[39]  D. Schiffer,et al.  Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.

[40]  P. Kushner,et al.  Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis , 1994, Journal of neuroscience research.

[41]  D. Burtrum,et al.  Hypoxic-Ischemic Brain Injury Stimulates Glial Fibrillary Acidic Protein mRNA and Protein Expression in Neonatal Rats , 1994, Experimental Neurology.

[42]  P. Schmitz,et al.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome , 1991, Muscle & nerve.

[43]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[44]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[45]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[46]  A. Pizzuti,et al.  ALS cerebrospinal fluid enhances human foetal astroglial cell proliferation in vitro. , 1987, Advances in experimental medicine and biology.